Traws Pharma Stock Surges 30% on Hantavirus Drug Development Plans
TL;DR
- · Traws Pharma announced advancement of clinical candidates for hantavirus treatment and prevention
- · Stock price jumped to $2.27, up 30% in Friday trading on Nasdaq
- · Company aims to develop therapeutic interventions targeting hantavirus infections
Traws Pharma stock climbed approximately 30 percent following the company's announcement to advance potential clinical candidates for hantavirus treatment and prevention. Shares rose to $2.27 during Friday trading, with the stock opening at $2.04 on the Nasdaq. The company's year-long trading range has spanned $0.97 to $3.27. This development signals continued investment in antiviral therapeutics targeting hantavirus, a genus of viruses that includes the Andes virus strain responsible for hemorrhagic fever with renal syndrome.
This is an AI-generated summary. For full reporting, read the original at rttnews.com →